• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.

作者信息

Rosati Margherita, Terpos Evangelos, Agarwal Mahesh, Karalis Vangelis, Bear Jenifer, Burns Robert, Hu Xintao, Papademetriou Demetrios, Ntanasis-Stathopoulos Ioannis, Trougakos Ioannis P, Dimopoulos Meletios-Athanasios, Pavlakis George N, Felber Barbara K

机构信息

Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

Am J Hematol. 2022 Jan 1;97(1):E3-E7. doi: 10.1002/ajh.26380. Epub 2021 Nov 5.

DOI:10.1002/ajh.26380
PMID:34674297
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8646236/
Abstract
摘要

相似文献

1
Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.SARS-CoV-2感染或疫苗接种诱导产生的抗体对刺突蛋白变体的独特中和谱。
Am J Hematol. 2022 Jan 1;97(1):E3-E7. doi: 10.1002/ajh.26380. Epub 2021 Nov 5.
2
Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.疫苗诱导产生的抗体水平与针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其变体的中和活性之间的相关性。
Clin Transl Med. 2021 Dec;11(12):e644. doi: 10.1002/ctm2.644.
3
A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.在 COVID-19 患者中接种一剂 mRNA 疫苗可提高针对 SARS-CoV-2 及关注变异株的中和抗体。
Cell Rep Med. 2021 Dec 14;3(1):100486. doi: 10.1016/j.xcrm.2021.100486. eCollection 2022 Jan 18.
4
Establishment of human post-vaccination SARS-CoV-2 standard reference sera.建立人接种 SARS-CoV-2 疫苗后标准参考血清。
J Immunol Methods. 2024 Jul;530:113698. doi: 10.1016/j.jim.2024.113698. Epub 2024 May 31.
5
Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.根据 BNT162b2 疫苗接种和感染史，抗 SARS-CoV-2 免疫球蛋白同种型和对病毒变异体的中和活性。
Front Immunol. 2021 Dec 17;12:793191. doi: 10.3389/fimmu.2021.793191. eCollection 2021.
6
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.评估新冠疫苗需要标准化的中和抗体检测。
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
7
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.接种疫苗后血清中针对新冠病毒变异株中和抗体的快速检测
J Mol Cell Biol. 2022 Jan 29;13(12):918-920. doi: 10.1093/jmcb/mjab050.
8
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.通过感染或接种疫苗，三次接触 SARS-CoV-2 的刺突蛋白会引发对所有令人关注的变异体更好的中和免疫。
Nat Med. 2022 Mar;28(3):496-503. doi: 10.1038/s41591-022-01715-4. Epub 2022 Jan 28.
9
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.奥密克戎变异株对抗体介导的中和作用具有高度抗性：对控制 COVID-19 大流行的影响。
Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.
10
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.恢复期血清和疫苗诱导的抗体对全球 SARS-CoV-2 变体刺突在很大程度上保持中和效价。
mBio. 2021 Jun 29;12(3):e0069621. doi: 10.1128/mBio.00696-21. Epub 2021 Jun 1.

引用本文的文献

1
Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study.SARS-CoV-2 感染后抗体反应的纵向分析取决于疾病严重程度：一项前瞻性队列研究。
Viruses. 2023 Nov 13;15(11):2250. doi: 10.3390/v15112250.
2
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
3
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
4
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies.检测严重急性呼吸综合征冠状病毒 2 抗体的临床效用。
Eur J Intern Med. 2023 Jan;107:7-16. doi: 10.1016/j.ejim.2022.11.009. Epub 2022 Nov 10.
5
Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV conserved elements in macaques.在恒河猴中比较针对 HIV 保守元件的 mRNA/LNP 疫苗和 DNA 疫苗的免疫原性。
Front Immunol. 2022 Jul 22;13:945706. doi: 10.3389/fimmu.2022.945706. eCollection 2022.
6
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.接种 BNT162b2 mRNA 疫苗的血液恶性肿瘤移植患者体内 SARS-CoV-2 抗体和固有细胞因子减少。
Front Immunol. 2022 May 25;13:899972. doi: 10.3389/fimmu.2022.899972. eCollection 2022.
7
Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.接种BNT162b2和AZD1222疫苗6个月后中和抗体反应的比较。
Biomedicines. 2022 Feb 1;10(2):338. doi: 10.3390/biomedicines10020338.
8
Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis.BNT162b2 全程接种九个月后中和抗体水平的预测因素：机器学习分析结果
Biomedicines. 2022 Jan 18;10(2):204. doi: 10.3390/biomedicines10020204.
9
Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece.BNT162b2疫苗第三剂可产生非常高水平的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的中和抗体：希腊150名卫生专业人员的前瞻性研究结果
Am J Hematol. 2022 Apr;97(4):E147-E150. doi: 10.1002/ajh.26468. Epub 2022 Jan 25.
10
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals.接种BNT162b2疫苗9个月后对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的持续但下降的体液免疫：309名健康个体的前瞻性评估
Hemasphere. 2021 Dec 17;6(1):e677. doi: 10.1097/HS9.0000000000000677. eCollection 2022 Jan.

本文引用的文献

1
Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）德尔塔变异株的传播事件揭示了多起疫苗突破性感染病例。
BMC Med. 2021 Oct 1;19(1):255. doi: 10.1186/s12916-021-02103-4.
2
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.恒河猴经 Spike DNA 或 Spike DNA+Protein 联合免疫后对 SARS-CoV-2 感染的控制。
PLoS Pathog. 2021 Sep 22;17(9):e1009701. doi: 10.1371/journal.ppat.1009701. eCollection 2021 Sep.
3
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals.第二剂 SARS-CoV-2 mRNA 疫苗对初免人群和 COVID-19 康复者 T 细胞免疫的差异影响。
Cell Rep. 2021 Aug 24;36(8):109570. doi: 10.1016/j.celrep.2021.109570. Epub 2021 Aug 4.
4
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.mRNA-1273疫苗诱导的针对SARS-CoV-2变体的抗体的持久性。
Science. 2021 Sep 17;373(6561):1372-1377. doi: 10.1126/science.abj4176. Epub 2021 Aug 13.
5
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.mRNA-脂质纳米颗粒疫苗候选物对 SARS-CoV-2 的安全性和免疫原性：一项 1 期随机临床试验。
Wien Klin Wochenschr. 2021 Sep;133(17-18):931-941. doi: 10.1007/s00508-021-01922-y. Epub 2021 Aug 10.
6
Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection.两剂 SARS-CoV-2 BNT162b2 疫苗可增强既往感染 SARS-CoV-2 个体对变异株的抗体反应。
Sci Transl Med. 2021 Sep;13(609):eabj0847. doi: 10.1126/scitranslmed.abj0847. Epub 2021 Aug 5.
7
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients.与 BNT162b2 mRNA 疫苗接种者对 SARS-CoV-2 产生有效免疫反应相关的系统性 IL-15、IFN-γ 和 IP-10/CXCL10 特征。
Cell Rep. 2021 Aug 10;36(6):109504. doi: 10.1016/j.celrep.2021.109504. Epub 2021 Jul 23.
8
Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021.2021 年 7 月，马萨诸塞州巴恩斯特布尔县与大型公众集会相关的 SARS-CoV-2 感染暴发，包括 COVID-19 疫苗突破性感染。
MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059-1062. doi: 10.15585/mmwr.mm7031e2.
9
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.新冠疫苗突破性感染在已接种疫苗的医护人员中发生。
N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28.
10
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.